We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. markets closed

EDAP TMS S.A. (EDAP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.1700+0.0400 (+0.97%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close4.1300
Open4.1800
Bid4.1600 x 3000
Ask4.2000 x 900
Day's Range4.1600 - 4.3700
52 Week Range1.4600 - 5.3900
Volume106,866
Avg. Volume94,609
Market Cap121.52M
Beta (5Y Monthly)2.17
PE Ratio (TTM)N/A
EPS (TTM)-0.0590
Earnings DateNov 18, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-36% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    EDAP TMS SA to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 19, 2020 / EDAP TMS SA (NASDAQ:EDAP) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 19, 2020 at 8:30 AM Eastern Time.

  • Benzinga

    Edap TMS: Q3 Earnings Insights

    Shares of Edap TMS (NASDAQ:EDAP) were flat after the company reported Q3 results.Quarterly Results Earnings per share decreased 233.33% over the past year to ($0.04), which missed the estimate of ($0.02).Revenue of $11,176,000 decreased by 1.36% from the same period last year, which beat the estimate of $9,290,000.Outlook Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: Nov 18, 2020View more earnings on EDAPTime: 08:30 AMET Webcast URL: http://public.viavid.com/player/index.php?id=142115Price Action Company's 52-week high was at $5.3952-week low: $1.46Price action over last quarter: Up 19.03%Company Overview Edap TMS SAis a holding company operating in two divisions namely, High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU division develops, manufactures and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets two HIFU devices: the Ablatherm, treatment of organ-confined prostate cancer; and the Focal One, for the focal therapy of localized prostate cancer destroying targeted cancer cells only. The UDS division develops, markets, manufactures and services medical devices for the invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The business of the presence of the firm are sen Asia, France, United States and other regions.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 18, 2020 * Earnings Outlook For Edap TMS(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • EDAP Reports Third Quarter 2020 Results and Provides Operational Update
    GlobeNewswire

    EDAP Reports Third Quarter 2020 Results and Provides Operational Update

    * Generated strongest total revenue quarter of 2020 * Reported growth in HIFU procedure revenues year-over-year notwithstanding ongoing COVID-19 pandemic * Completed sales to renowned healthcare institutions Mount Sinai Health System in New York and Keck Medical Center at the University of Southern California * Announced first patients treated in Phase 2 clinical trial assessing Focal One® as a potential treatment for deep rectal endometriosis * Increased strong cash position to EUR 19.9 million (USD 23.4 million) as of September 30, 2020 * Company to host a conference call tomorrow, November 19th, at 8:30 am ET LYON, France, November 18, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy based therapies, announced today financial results for the third quarter of 2020 and provided an update on strategic and operational developments. Marc Oczachowski, EDAP's Chairman and Chief Executive Officer, said: “The third quarter of 2020 was our strongest of the year thus far, a clear signal that we are successfully navigating through the challenges posed by the ongoing COVID-19 pandemic. We closed several notable transactions during the quarter, including a bundled Focal One-ExactVu sale to Mount Sinai Health System in New York, and a Focal One sale to Keck Medical Center of University of Southern California, an early adopter of our first generation HIFU technology, Ablatherm®. At the same time, we continued to grow our sales pipeline, both in the U.S. and internationally.“Also, during the quarter, we received regulatory approval to initiate a Phase 2 study assessing Focal One® as a potential treatment for deep rectal endometriosis and we initiated patient treatments quickly thereafter. Endometriosis represents an important expansion of our development pipeline as we work to maximize the clinical utility of HIFU across new indications beyond prostate.    “We ended the quarter with a strong cash position of $23.4 million, sufficient to continue to execute on our Focal One-ExactVu commercial plan while advancing HIFU in endometriosis and other soft tissue indications where we believe this non-invasive technology can be beneficial.“With COVID cases again rising in many parts of the world, including most of the US, we are carefully monitoring the effect on our operations during the fourth quarter. While we are seeing some impact on procedure volumes as hospitals continue to focus on the pandemic, we are nonetheless optimistic that we will be able to announce additional sales by the end of the year,” Mr. Oczachowski concluded.  Third Quarter 2020 Results Total revenue for the third quarter 2020 was EUR 9.4 million (USD 11.2 million), a decrease of 8.5% compared to total revenue of EUR 10.3 million (USD 11.3 million) for the same period in 2019. Third quarter 2020 revenue reflects the impact of the ongoing COVID-19 pandemic on equipment sales. Total revenue in the HIFU business for the third quarter 2020 was EUR 2.6 million (USD 3.0 million), a 7.9% decrease compared to EUR 2.8 million (USD 3.1 million) for the third quarter of 2019. Total revenue in the LITHO business for the third quarter 2020 was EUR 2.4 million (USD 2.9 million), a 27.6% decrease compared to EUR 3.3 million (USD 3.7 million) for the third quarter of 2019Total revenue in the Distribution business for the third quarter 2020 was EUR 4.4 million (USD 5.2 million), a 6.4% increase compared to EUR 4.2 million (USD 4.6 million) for the third quarter of 2019.Gross profit for the third quarter 2020 was EUR 4.0 million (USD 4.7 million), compared to EUR 4.7 million (USD 5.1 million) for the year-ago period. Gross profit margin on net sales was 42.0% in the third quarter of 2020, compared to 45.3% in the year-ago period. The decline in gross profit year-over-year was due to in part to lower sales in HIFU business as compared to the year-ago period driven primary by COVID-19.Operating expenses were EUR 4.3 million (USD 5.0 million) for the third quarter of 2020, compared to EUR 4.4 million (USD 4.9 million) for the same period in 2019.Operating loss for the third quarter of 2020 was EUR 0.3 million (USD 0.3 million), compared to an operating profit of EUR 0.3 million (USD 0.3 million) in the third quarter of 2019. Net loss for the third of 2020 was EUR 1.0 million (USD 1.2 million), or EUR (0.03) per diluted share, as compared to net income of EUR 0.8 million (USD 0.9 million), or EUR 0.03 per diluted share in the year-ago period.For the first nine months 2020 ResultsTotal revenue for the first nine months of 2020 was EUR 26.3 million (USD 29.8 million), a decrease of 20.1% compared to total revenue of EUR 32.9 million (USD 36.9 million) for the same period in 2019. As mentioned, year-to-date revenue reflects the impact of the ongoing COVID-19 pandemic on the company’s activities. Total revenue in the HIFU business for the first nine months of 2020 was EUR 7.1 million (USD 8.0 million), a 37.2% decrease compared to EUR 11.2 million (USD 12.6 million) for the first nine months of 2019. Total revenue in the LITHO business for the first nine months of 2020 was EUR 8.3 million (USD 9.4 million), a 17.8% decrease compared to EUR 10.1 million (USD 11.3 million) for the first nine months of 2019. Total revenue in the Distribution business for the first nine months of 2020 was EUR 11.0 million (USD 12.4 million), a 5.6% decrease compared to EUR 11.6 million (USD 13.0 million) for the first nine month of 2019. Gross profit for the first nine months of 2020 was EUR 11.4 million (USD 12.8 million), compared to EUR 15.9 million (USD 17.8 million) for the year-ago period. Gross profit margin on net sales was 43.2% for the first nine months of 2020, compared to 48.2% in the year-ago period. The decline in gross profit year-over-year was due in part to lower sales in the HIFU business driven by COVID-19.Operating expenses were EUR 12.8 million (USD 14.5 million) for the first nine months of 2020, compared to EUR 13.7 million (USD 15.4 million) for the same period in 2019.Operating loss for the first nine months of 2020 was EUR 1.5 million (USD 1.6 million), compared to an operating profit of EUR 2.1 million (USD 2.4 million) for the same period of 2019. Net loss for the first nine months of 2020 was EUR 2.5 million (USD 2.8 million), or EUR (0.09) per diluted share, as compared to a net income of EUR 2.5 million (USD 2.8 million), or EUR 0.09 per diluted share in the year-ago period.As of September 30, 2020, the Company recorded a strong cash position of EUR 19.9 million (USD 23.4 million).  Conference CallAn accompanying conference call and webcast will be conducted by management to review the results. The call will be held at 8:30am EDT tomorrow, November 19, 2020. Please refer to the information below for conference call dial-in information and webcast registration.Conference Call & Webcast Thursday, November 19, 2020 @ 8:30am Eastern Time Domestic:                             877-451-6152 International:                      201-389-0879 Passcode:                             13712293 Webcast:                              http://public.viavid.com/index.php?id=142115Following the live call, a replay will be available on the Company's website, www.edap-tms.com under "Investors Information."About EDAP TMS SAA recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.  EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com. Forward-Looking StatementsIn addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as the length and severity of the COVID-19 pandemic, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.Company Contact Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 50 bconfort@edap-tms.comInvestor Contact Jeremy Feffer LifeSci Advisors, LLC 212-915-2568 jeremy@lifesciadvisors.com EDAP TMS S.A. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands of Euros and U.S. Dollars, except per share data)  Three  Months Ended:   Three Months Ended:     Sept. 30, 2020 Euros     Sept. 30, 2019 Euros   Sept. 30, 2020 $US   Sept. 30, 2019 $US   Sales of medical equipment 5,984   6,877   7,080   7,571   Net Sales of RPP and Leases 1,207   1,228   1,428   1,352   Sales of spare parts, supplies and Services 2,255   2,187   2,668   2,407   TOTAL NET SALES 9,446   10,292   11,176   11,330   Other revenues (13)   15   (16)   17   TOTAL REVENUES 9,433   10,307   11,160   11,347   Cost of sales (5,469)   (5,641)   (6,470)   (6,209)   GROSS PROFIT 3,964   4,667   4,690   5,137   Research & development expenses (1,090)   (886)   (1,289)   (975)   S, G & A expenses (3,167)   (3,522)   (3,748)   (3,877)   Total operating expenses (4,257)   (4,408)   (5,037)   (4,852)   OPERATING PROFIT (LOSS) (293)   259   (347)   285   Interest (expense) income, net (12)   (40)   (14)   (44)   Currency exchange gains (loss), net (574)   684   (679)   753   INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST (879)   903   (1,040)   994   Income tax (expense) credit (122)   (120)   (145)   (132)   NET INCOME (LOSS)   (1,001)   783   (1,185)   862   Earning per share – Basic (0.03)   0.03   (0.04)   0.03   Average number of shares used in computation of EPS 29,144,010   28,997,886   29,144,010   28,997,886   Earning per share – Diluted (0.03)   0.03   (0.04)   0.03   Average number of shares used in computation of EPS for positive net income   29,144,010   29,622,866   29,144,010   29,622,866   NOTE:  Translated for convenience of the reader to U.S. dollars at the 2020 average three months’ noon buying rate of 1 Euro = 1.1832 USD, and 2019 average three months noon buying rate of 1 Euro = 1.1008 USD EDAP TMS S.A. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands of Euros and U.S. Dollars, except per share data)  Nine Months Ended:   Nine Months Ended:     Sept. 30, 2020 Euros     Sept. 30, 2019 Euros   Sept. 30, 2020 $US   Sept. 30, 2019 $US   Sales of medical equipment 16,083   22,139   18,204   24,797   Net Sales of RPP and Leases 3,409   4,028   3,858   4,512   Sales of spare parts, supplies and Services 6,795   6,742   7,691   7,551   TOTAL NET SALES 26,287   32,909   29,753   36,860   Other revenues 11   15   12   17   TOTAL REVENUES 26,298   32,924   29,765   36,877   Cost of sales (14,948)   (17,061)   (16,919)   (19,110)   GROSS PROFIT 11,350   15,863   12,846   17,768   Research & development expenses (3,058)   (2,884)   (3,461)   (3,231)   S, G & A expenses (9,743)   (10,857)   (11,027)   (12,161)   Total operating expenses (12,800)   (13,742)   (14,488)   (15,392)   OPERATING PROFIT (LOSS) (1,451)   2,121   (1,642)   2,376   Interest (expense) income, net (51)   (103)   (58)   (115)   Currency exchange gains (loss), net (631)   788   (714)   883   INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST (2,133)   2,807   (2,415)   3,144   Income tax (expense) credit (351)   (317)   (397)   (356)   NET INCOME (LOSS)   (2,484)   2,490   (2,812)   2,789   Earning per share – Basic (0.09)   0.09   (0.10)   0.10   Average number of shares used in computation of EPS 29,142,788   28,997,866   29,142,788   28,997,866   Earning per share – Diluted (0.09)   0.08   (0.10)   0.09   Average number of shares used in computation of EPS for positive net income   29,142,788   29,623,683   29,142,788   29,623,683   NOTE:  Translated for convenience of the reader to U.S. dollars at the 2020 average nine months’ noon buying rate of 1 Euro = 1.1319 USD, and 2019 average nine months noon buying rate of 1 Euro = 1.1201 USD  EDAP TMS S.A. UNAUDITED CONSOLIDATED BALANCE SHEETS HIGHLIGHTS (Amounts in thousands of Euros and U.S. Dollars)    Sept. 30, 2020 Euros     June. 30, 2020 Euros   Sept. 30, 2020 $US   June 30, 2020 $US Cash, cash equivalents and short-term treasury investments 19,929   15,704   23,364   17,647   Account receivables, net 11,572   12,607   13,567   14,167   Inventory 9,455   9,365   11,084   10,523   Other current assets 604   631   708   709   TOTAL CURRENT ASSETS 41,560   38,307   48,722   43,046   Property, plant and equipment, net 5,928   6,072   6,950   6,823   Goodwill 2,412   2,412   2,827   2,710   Other non-current assets 1,739   1,794   2,039   2,016   TOTAL ASSETS 51,639   48,585   60,538   54,596   Accounts payable & other accrued liabilities 9,122   9,618   10,694   10,808   Deferred revenues, current portion 2,695   2,519   3,160   2,831   Short term borrowing 1,459   887   1,711   997   Other current liabilities 5,825   1,820   6,829   2,045   TOTAL CURRENT LIABILITIES 19,102   14,845   22,394   16,681   Obligations under operating and finance leases non-current 1,724   1,906   2,021   2,141   Long term debt, non-current 1,219   1,193   1,429   1,341   Deferred revenues, non-current 821   1,100   963   1,236   Other long term liabilities 3,626   3,673   4,251   4,128   TOTAL LIABILITIES 26,493   22,717   31,059   25,528   TOTAL SHAREHOLDERS’EQUITY 25,146   25,867   29,480   29,068   TOTAL LIABILITIES & SHAREHOLDERS’ EQUITY 51,639    48,585   60,538   54,596   NOTE: Translated for convenience of the reader to U.S. dollars at the noon buying rate of 1 Euro = 1.1723 USD, on September 30, 2020 and at the noon buying rate of 1 Euro = 1.1237 USD, on June 30, 2020.EDAP TMS S.A. UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (Amounts in thousands of Euros)  Sept. 30, 2020 Euros     June 30, 2020       Euros   Sept. 30, 2020 $US   June 30      2020 $US NET INCOME (LOSS) (2,484)   (1,483)   (2,812)   (1,640) Adjustments to reconcile net income (loss) to net cash generated by (used in) operating activities 2,211       1,457       2,503       1,612 OPERATING CASH FLOW (273)   (25)   (309)   (28) Increase/Decrease in operating assets and liabilities (1,735)   (1,774)   (1,964)   (1,963) NET CASH GENERATED BY (USED IN) OPERATING ACTIVITIES (2,008)   (1,799)   (2,273)   (1,991) Short term investments(1) (1,708)   (1,786)   (1,933)   (1,976) Additions to capitalized assets produced by the company and other capital expenditures (1,508)   (844)   (1,707)   (933) NET CASH GENERATED BY (USED IN) INVESTING ACTIVITIES (3,216)   (2,630)   (3,640)   (2,909) NET CASH GENERATED BY (USED IN) FINANCING ACTIVITIES 2,248   (2,444)   2,544   (2,704) NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS 312   (44)   1,281   (204) NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (2,665)   (6,968)   (2,088)   (7,808) (1) Short term investments are comprised of money market fundsNOTE:  Translated for convenience of the reader to U.S. dollars at the 2020 average nine months’ noon buying rate of 1 Euro = 1.1319 USD, and 2019 average nine months noon buying rate of 1 Euro = 1.1201 USD     EDAP TMS S.A. UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION NINE MONTHS ENDED SEPTEMBER 30, 2020 (Amounts in thousands of Euros)      HIFU Division     ESWL Division     Distribution Division     Reconciling Items     Total After Consolidation     Sales of goods   3,095     3,408     9,580         16,083   Sales of RPPs & Leases 2,594   659   156       3,409   Sales of spare parts & services 1,351   4,217   1,226       6,795   TOTAL NET SALES   7,041   8,284   10,962       26,287   Other revenues   11   0   0       11   TOTAL REVENUES 7,052   8,284   10,962       26,298   GROSS PROFIT (% of Total Revenues) 3,877 55.0 % 3,490 42.1% 3,982 36.3%     11,350 43.2%   Research & Development   (1,763)   (1,006)   (289)       (3,058)   Total SG&A plus depreciation (2,870)   (2,154)   (3,599)   (1,119)   (9,743)     OPERATING PROFIT (LOSS)   (756)     331     94     (1,119)     (1,451)    Attachment * 2020-11-18 -- EDAP 3Q 2020 Press Release Final

  • Benzinga

    Earnings Outlook For Edap TMS

    Edap TMS (NASDAQ: EDAP) announces its next round of earnings this Wednesday, November 18. Here is Benzinga's everything-that-matters guide for this Wednesday's Q3 earnings announcement.Net Income, Earnings, And Earnings Per Share Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding.Earnings And Revenue Sell-side analysts are expecting Edap TMS's loss per share to be near $0.02 on sales of $9.31 million. Edap TMS EPS in the same period a year ago totaled $0.03. Sales were $11.33 million.What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values.View more earnings on EDAPIf the company were to post earnings in line with the consensus estimate when it reports Wednesday, EPS would be down 166.67%. Revenue would be down 17.83% from the same quarter last year. Here is how the company's reported EPS has stacked up against analyst estimates in the past:Quarter Q2 2020 Q1 2020 Q4 2020 Q3 2019 EPS Estimate -0.08 -0.03 0.03 0.04 EPS Actual -0.01 -0.05 -0.04 0.03 Revenue Estimate 6.72 M 9.16 M 13.99 M 12.94 M Revenue Actual 10.24 M 8.29 M 13.30 M 11.33 M Stock Performance Over the past 52-week period, shares of Edap TMS have declined 7.02%. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.Do not be surprised to see the stock move on comments made during its conference call. Edap TMS is scheduled to hold the call at 08:30:00 ET and can be accessed here.See more from Benzinga * Click here for options trades from Benzinga * Earnings Outlook For NVIDIA * P/E Ratio Insights for Sempra Energy(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • EDAP Announces Exclusive Distribution Agreement with Leading Italian Medical Device Distributor AB Medica
    GlobeNewswire

    EDAP Announces Exclusive Distribution Agreement with Leading Italian Medical Device Distributor AB Medica

    * Partnership further extends the availability of EDAP’s High Intensity Focused Ultrasound (HIFU) technology to one of the largest markets in Europe * Complementary to AB Medica’s extensive product portfolio which includes robotic surgery solutions as well as ExactVu LYON, France, November 17, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, announced today that the company has signed an exclusive distribution agreement with AB Medica, a leading distribution of medical technologies across Italy. Marc Oczachowski, Chairman and Chief Executive Officer of EDAP, commented: “We are very pleased to partner with AB Medica, a widely recognized leader in Italy for the distribution of cutting-edge medical technologies. This is clearly a step forward for EDAP in its HIFU adoption and commercialization program in Europe, as Italy is the fourth largest market for medical devices. Notably, AB Medica had already been distributing ExactVu, so they are familiar with our product line and have been able to incorporate Focal One very quickly. AB Medica also has extensive experience in the distribution of robotic prostate surgery solutions, so they are the perfect fit for us. We look forward to a very successful partnership.” Filippo Pacinotti, Business Director of AB Medica, stated: “We are thrilled to have entered into this distribution agreement with EDAP, which is already a highly recognized name in Italy. This partnership will not only see us strengthen our presence in high definition ultrasound with ExactVu, but will also give us the opportunity to become a reference point in lithotripsy and HIFU, rounding out what will be an outstanding urology product portfolio. We are confident that we will meet EDAP’s expectations, and we are eager to start this new adventure with great enthusiasm.”About EDAP TMS SAA recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.  EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.   About AB Medica Founded in 1984 by Aldo Cerruti, still the company’s President, ab medica is now Italy’s leading company in the production and distribution of medical technologies, as well as a reference point for robotic surgery and technological innovation in healthcare. Excellence, quality, technological innovation and competitiveness all rotate around our single mission which is to put people and their wellbeing at the centre of every one of our activities. Thanks to its synergistic collaboration with other companies in the holding, ab medica has now acquired a leading role in the field of Research & Development, with important projects and solutions in sectors such as genomics, tissue engineering and stem cells, together with intensified relations with universities, research centres and international scientific laboratories. For more information on the company, please visit their website www.abmedica.it/en/.Forward-Looking StatementsIn addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device, as well as the length and severity of the recent COVID-19 outbreak, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.Company Contact Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 50 bconfort@edap-tms.comInvestor Contact Jeremy Feffer LifeSci Advisors, LLC 212-915-2568 jeremy@lifesciadvisors.com

  • EDAP Announces Presentation at the Jefferies Virtual London Healthcare Conference
    GlobeNewswire

    EDAP Announces Presentation at the Jefferies Virtual London Healthcare Conference

    LYON, France, November 10, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that management will be presenting at the Jefferies Virtual London Healthcare Conference, which is being held November 17-19, 2020. Presentation Details Date: Tuesday, November 17 Time: 10:00am BT Webcast: https://wsw.com/webcast/jeff141/edap/1815450 The webcast will be archived and available for replay for a period of 90 days.About EDAP TMS SAA recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.  EDAP TMS also produces and distributes other medical equipment such as the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.Forward-Looking Statements In addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the sustained  activity of our lithotripsy business, as well as the length and severity of the recent COVID-19 outbreak, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.Company Contact Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 50 bconfort@edap-tms.comInvestor Contact Jeremy Feffer LifeSci Advisors, LLC 212-915-2568 jeremy@lifesciadvisors.com

  • EDAP TMS SA to Announce Third Quarter 2020 Financial Results on November 18, 2020
    GlobeNewswire

    EDAP TMS SA to Announce Third Quarter 2020 Financial Results on November 18, 2020

    Company to host conference call and webcast on Thursday, November 19 at 8:30 am EDTLYON, France, November 9, 2020 \- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the third quarter ended September 30, 2020 after the markets close on Wednesday, November 18, 2020.An accompanying conference call and webcast will be conducted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Thursday, November 19, 2020. Please refer to the information below for conference call dial-in information and webcast registration.Conference Call & Webcast Thursday, November 19th @ 8:30am Eastern Time Domestic:                    877-451-6152 International:              201-389-0879 Passcode:                    13712293 Webcast:                     http://public.viavid.com/index.php?id=142115About EDAP TMS SAA recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.  EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.CONTACTS: Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 50 bconfort@edap-tms.comInvestor Contact Jeremy Feffer LifeSci Advisors, LLC 212-915-2568 jeremy@lifesciadvisors.com

  • EDAP TMS' Shares March Higher, Can It Continue?
    Zacks

    EDAP TMS' Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in EDAP TMS.

  • GlobeNewswire

    EDAP Hosting Key Opinion Leader Call on Focal One® and ExactVu™

    Call to be Held Tuesday, September 22nd @ 8am Eastern TimeLYON, France, September 15, 2020 \-- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will host a key opinion leader (KOL) call on its two lead commercial products, Focal One® and ExactVu™, on Tuesday, September 22nd at 8am Eastern Time.The call will feature a presentation by Key Opinion Leaders (KOL) Brian Miles, MD (Houston Methodist) and Laurence Klotz, MD (Sunnybrook Health Sciences Centre) who will discuss the opportunity for the Focal One® High Intensity Focused Ultrasound (HIFU) system and the ExactVu™ micro-ultrasound. Drs. Miles and Klotz will be available to answer questions at the conclusion of the call.EDAP TMS's management team will also give an update on the sales successes they are seeing for both stand-alone solutions as well as bundled deals, as well as the additional pipeline expansion opportunities that exist for these technologies beyond prostate cancer.By combining the latest imaging and ablation technologies, Focal One® brings the answer to current requirements for ideal focal therapy: accurate MRI and 3D Biopsy image fusion, non-invasive approach, as well as precise and efficient HIFU energy. This is the industry’s first end-to-end solution for the urology suite.The ExactVu™ micro-ultrasound platform provides the most practical solution as a new tool for urologists or radiologists to perform targeted biopsies within a standard urological workflow and is the only ultrasound-based imaging tool with published data demonstrating prostate cancer diagnostic capabilities similar to MRI. The unique 29MHz frequency allows urologists to visualize details unseen before in any prostate ultrasound image, detect suspicious areas in real-time and take a biopsy sample as representative of the level of aggressiveness of the cancer.To register for the call, please click here.Brian J. Miles, MD is a board-certified urologist at Houston Methodist in Houston, Texas. Dr. Miles is a Professor of Urology at Weill Cornell Medical College of Cornell University and Baylor College of Medicine. Additionally, he is the Medical Director of Robotic Surgery at The Methodist Hospital and the physician in charge of Surgical Robot Training. Having served as the Director of the Urology Residency Program at Baylor College of Medicine, he continues to educate and provide professional direction to medical students, urology residents, and fellow urologists. Dr. Miles specializes in urologic oncology, especially cancer of the prostate.Dr. Miles’ primary focus and interest in clinical practice and research is in the detection and surgical treatment of prostate cancer, bladder cancer and kidney cancer. As one of the leading authorities in Texas and the country in the use of the daVinci robot surgical system, he has performed over 2,200 robotic prostatectomies (removal of the prostate), and many robotic cystectomies (removal of the bladder), and partial nephrectomies (removal of part of the kidney) procedures. In addition, Dr. Miles is the physician instructor for surgeons wishing to learn this procedure in the Houston metropolitan area. He also travels widely as a lecturer, surgeon, and consultant on urological cancers to many foreign countries.Dr. Miles has authored of over one hundred and seventy-five, peer-reviewed scientific papers and book chapters, and have worked with Dr. Peter Scardino as the associate editor of the landmark textbook, Comprehensive Textbook of Genitourinary Oncology. Dr. Miles is consistently listed in Best Cancer Doctors in America, America’s Top Doctors, Best Doctors in America and Texas Super Doctor in Texas Monthly.Dr. Laurence Klotz was educated at the University of Toronto, Ontario, where in 1977 he obtained his MD. Dr. Klotz completed his residency at the University of Toronto in 1983. Subsequently, he was a Fellow in Uro-Oncology and Tumor Biology at the Memorial Sloan Kettering Cancer Center in New York, completing it in 1985. Dr. Klotz then returned to Sunnybrook Health Sciences Centre in Toronto.  He is an Associate Scientist at the Sunnybrook Research Institute, the past Chief of Urology, Professor of Surgery at the University of Toronto, and holds the Sunnybrook Chair of Prostate Cancer Research. Dr. Klotz is a widely published uro-oncologist (470 peer review publications, 6 books).  His basic research interests have included research in the role of micronutrients and diet in prostate cancer prevention, and translational research in biomarkers and imaging. His research lab has been active for 30 years, producing several patents and a biotech company. His clinical research interests have been in the areas of active surveillance, image guided therapy, molecular biomarkers, and androgen receptor targeted therapy.  He has led numerous randomized trials in prostate cancer. Dr. Klotz was awarded the Queen’s Jubilee Medal in 2013 for meritorious public service, and the University of Toronto Department of Surgery Lister Prize for outstanding research contributions and the Society of Urologic Oncology Medal in 2014. In 2015 he received Canada’s highest civilian award, the Order of Canada, and the Harold Warwick Prize from the Canadian Cancer Society for international contributions to cancer control. The AUA presented him the Richard Williams Award for outstanding contributions in urologic oncology in 2016. He has received Lifetime Achievement Awards from the University of Toronto in 2017 and the Canadian Urological Association in 2019. He also received the Huggins medal from the SUO in 2019.About EDAP TMS SA A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA-cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems. For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.Forward-Looking Statements In addition to historical information, this press release contains forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the sustained  activity of our lithotripsy business, as well as the length and severity of the recent COVID-19 outbreak, including its impacts across our businesses on demand for our devices and services. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.Company Contact Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 50 bconfort@edap-tms.comInvestor Contact Jeremy Feffer LifeSci Advisors, LLC 212-915-2568 jeremy@lifesciadvisors.com

  • EDAP's Shares March Higher, Can It Continue?
    Zacks

    EDAP's Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor EDAP TMS.